Jazz Pins Sativex US Hopes On Two Advanced Studies After First MS Spasticity Trial Flunks

29 Jun 2022

• By Ayisha Sharma

The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.

Sativex Contains Several Cannabis Derivatives Including THC And CBD • Source: Shutterstock

Jazz Pharmaceuticals plc has hit a stumbling block in its bid to get the cannabis-derived nabiximols spray product finally onto the market in the US after it failed in the first of three Phase III trials in multiple sclerosis spasticity.

Jazz got hold of the nabiximols spray product via its $7.2bn acquisition of cannabinoid specialist GW Pharmaceuticals plc completed last year, which also brought with it the epilepsy drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.